UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014

By: Benzinga
In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Infinity Pharmaceuticals (NASDAQ: INFI ) from Outperform to Neutral, but reiterated the $20.00 price target. In the report, Credit Suisse noted, “We are downgrading INFI to Neutral because (1) limited clinical data is expected in 2014,
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.